nodes	percent_of_prediction	percent_of_DWPC	metapath
Rasagiline—CYP1A2—Thalidomide—leprosy	0.269	0.508	CbGbCtD
Rasagiline—CYP1A2—Rifampicin—leprosy	0.261	0.492	CbGbCtD
Rasagiline—Emphysema—Thalidomide—leprosy	0.0223	0.0582	CcSEcCtD
Rasagiline—Footdrop—Thalidomide—leprosy	0.0203	0.053	CcSEcCtD
Rasagiline—Anaemia macrocytic—Thalidomide—leprosy	0.0187	0.0487	CcSEcCtD
Rasagiline—Peroneal nerve palsy—Thalidomide—leprosy	0.0173	0.0451	CcSEcCtD
Rasagiline—BCL2—IL2 signaling events mediated by STAT5—LTA—leprosy	0.012	0.139	CbGpPWpGaD
Rasagiline—Arterial thrombosis—Thalidomide—leprosy	0.00869	0.0227	CcSEcCtD
Rasagiline—MAOB—Alpha-synuclein signaling—PARK2—leprosy	0.00752	0.0868	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—TNFSF15—leprosy	0.0075	0.0866	CbGpPWpGaD
Rasagiline—Circumoral paresthesia—Thalidomide—leprosy	0.00718	0.0187	CcSEcCtD
Rasagiline—Albuminuria—Dapsone—leprosy	0.00612	0.016	CcSEcCtD
Rasagiline—Intestinal perforation—Thalidomide—leprosy	0.00592	0.0154	CcSEcCtD
Rasagiline—Dementia—Thalidomide—leprosy	0.0057	0.0149	CcSEcCtD
Rasagiline—BCL2—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—CYLD—leprosy	0.00563	0.0651	CbGpPWpGaD
Rasagiline—Dysaesthesia—Thalidomide—leprosy	0.00541	0.0141	CcSEcCtD
Rasagiline—BCL2—Apoptosis—LTA—leprosy	0.00528	0.061	CbGpPWpGaD
Rasagiline—Paraesthesia oral—Thalidomide—leprosy	0.00499	0.013	CcSEcCtD
Rasagiline—Hernia—Thalidomide—leprosy	0.00499	0.013	CcSEcCtD
Rasagiline—Cerebral ischaemia—Thalidomide—leprosy	0.00484	0.0126	CcSEcCtD
Rasagiline—Hostility—Thalidomide—leprosy	0.00423	0.011	CcSEcCtD
Rasagiline—BCL2—FAS pathway and Stress induction of HSP regulation—RIPK2—leprosy	0.00417	0.0482	CbGpPWpGaD
Rasagiline—Sexual dysfunction—Thalidomide—leprosy	0.00417	0.0109	CcSEcCtD
Rasagiline—Vesiculobullous rash—Thalidomide—leprosy	0.00417	0.0109	CcSEcCtD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—SLC11A1—leprosy	0.00414	0.0478	CbGpPWpGaD
Rasagiline—Gastric ulcer—Thalidomide—leprosy	0.00403	0.0105	CcSEcCtD
Rasagiline—Myasthenia—Thalidomide—leprosy	0.00372	0.00971	CcSEcCtD
Rasagiline—BCL2—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—RIPK2—leprosy	0.00363	0.0419	CbGpPWpGaD
Rasagiline—Intestinal obstruction—Thalidomide—leprosy	0.00343	0.00896	CcSEcCtD
Rasagiline—Neuralgia—Thalidomide—leprosy	0.00337	0.00879	CcSEcCtD
Rasagiline—Interstitial lung disease—Thalidomide—leprosy	0.00331	0.00863	CcSEcCtD
Rasagiline—BCL2—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—NOD2—leprosy	0.00329	0.038	CbGpPWpGaD
Rasagiline—Psychotic disorder—Dapsone—leprosy	0.00324	0.00846	CcSEcCtD
Rasagiline—Albuminuria—Thalidomide—leprosy	0.00313	0.00818	CcSEcCtD
Rasagiline—Stupor—Thalidomide—leprosy	0.00313	0.00818	CcSEcCtD
Rasagiline—Neuritis—Thalidomide—leprosy	0.00313	0.00818	CcSEcCtD
Rasagiline—Pleural effusion—Thalidomide—leprosy	0.00306	0.00797	CcSEcCtD
Rasagiline—Skin ulcer—Thalidomide—leprosy	0.00301	0.00784	CcSEcCtD
Rasagiline—Rash pustular—Thalidomide—leprosy	0.00293	0.00766	CcSEcCtD
Rasagiline—Muscular weakness—Dapsone—leprosy	0.00293	0.00764	CcSEcCtD
Rasagiline—Influenza—Dapsone—leprosy	0.00287	0.00748	CcSEcCtD
Rasagiline—Apnoea—Thalidomide—leprosy	0.00276	0.0072	CcSEcCtD
Rasagiline—Amenorrhoea—Thalidomide—leprosy	0.00266	0.00695	CcSEcCtD
Rasagiline—Accidental injury—Thalidomide—leprosy	0.00264	0.0069	CcSEcCtD
Rasagiline—Photosensitivity reaction—Dapsone—leprosy	0.00262	0.00683	CcSEcCtD
Rasagiline—Arthropathy—Thalidomide—leprosy	0.00257	0.00671	CcSEcCtD
Rasagiline—Hypocalcaemia—Thalidomide—leprosy	0.00256	0.00667	CcSEcCtD
Rasagiline—Drug interaction—Thalidomide—leprosy	0.00252	0.00658	CcSEcCtD
Rasagiline—Neuropathy peripheral—Dapsone—leprosy	0.00251	0.00654	CcSEcCtD
Rasagiline—Dyskinesia—Thalidomide—leprosy	0.00249	0.0065	CcSEcCtD
Rasagiline—Gait disturbance—Thalidomide—leprosy	0.0024	0.00626	CcSEcCtD
Rasagiline—Coordination abnormal—Thalidomide—leprosy	0.00238	0.00622	CcSEcCtD
Rasagiline—Neck pain—Thalidomide—leprosy	0.00237	0.00618	CcSEcCtD
Rasagiline—BCL2—Overview of nanoparticle effects—TNF—leprosy	0.0023	0.0265	CbGpPWpGaD
Rasagiline—Depressed level of consciousness—Thalidomide—leprosy	0.00226	0.0059	CcSEcCtD
Rasagiline—Colitis—Thalidomide—leprosy	0.00225	0.00586	CcSEcCtD
Rasagiline—Neuropathy—Thalidomide—leprosy	0.0022	0.00573	CcSEcCtD
Rasagiline—BCL2—IL2 signaling events mediated by STAT5—IL2—leprosy	0.00219	0.0253	CbGpPWpGaD
Rasagiline—Cramps of lower extremities—Thalidomide—leprosy	0.00215	0.00561	CcSEcCtD
Rasagiline—Oesophagitis—Thalidomide—leprosy	0.00214	0.00558	CcSEcCtD
Rasagiline—Gynaecomastia—Thalidomide—leprosy	0.00209	0.00546	CcSEcCtD
Rasagiline—Hypertonia—Thalidomide—leprosy	0.00205	0.00535	CcSEcCtD
Rasagiline—Hyperkinesia—Thalidomide—leprosy	0.00204	0.00532	CcSEcCtD
Rasagiline—Thrombophlebitis—Thalidomide—leprosy	0.00196	0.00512	CcSEcCtD
Rasagiline—Gastroenteritis—Thalidomide—leprosy	0.00192	0.005	CcSEcCtD
Rasagiline—Deafness—Thalidomide—leprosy	0.0019	0.00495	CcSEcCtD
Rasagiline—Vascular purpura—Thalidomide—leprosy	0.0019	0.00495	CcSEcCtD
Rasagiline—Eczema—Thalidomide—leprosy	0.00189	0.00493	CcSEcCtD
Rasagiline—Eye pain—Thalidomide—leprosy	0.00188	0.00491	CcSEcCtD
Rasagiline—BCL2—IL2 signaling events mediated by PI3K—IL2—leprosy	0.00185	0.0214	CbGpPWpGaD
Rasagiline—Injury—Thalidomide—leprosy	0.00185	0.00482	CcSEcCtD
Rasagiline—Renal failure acute—Thalidomide—leprosy	0.00184	0.0048	CcSEcCtD
Rasagiline—Libido decreased—Thalidomide—leprosy	0.00183	0.00478	CcSEcCtD
Rasagiline—Amnesia—Thalidomide—leprosy	0.00181	0.00472	CcSEcCtD
Rasagiline—Dermatitis exfoliative—Thalidomide—leprosy	0.0018	0.0047	CcSEcCtD
Rasagiline—Vertigo—Dapsone—leprosy	0.0018	0.00468	CcSEcCtD
Rasagiline—BCL2—RXR and RAR heterodimerization with other nuclear receptor—TNF—leprosy	0.00179	0.0206	CbGpPWpGaD
Rasagiline—Dermatitis bullous—Thalidomide—leprosy	0.00178	0.00464	CcSEcCtD
Rasagiline—Purpura—Thalidomide—leprosy	0.00176	0.0046	CcSEcCtD
Rasagiline—Arthritis—Thalidomide—leprosy	0.00175	0.00456	CcSEcCtD
Rasagiline—Cough—Dapsone—leprosy	0.00174	0.00455	CcSEcCtD
Rasagiline—Cardiac failure—Thalidomide—leprosy	0.00174	0.00454	CcSEcCtD
Rasagiline—BCL2—IL-5 Signaling Pathway—IL2—leprosy	0.00174	0.0201	CbGpPWpGaD
Rasagiline—Cerebrovascular accident—Thalidomide—leprosy	0.00173	0.00452	CcSEcCtD
Rasagiline—Gastrointestinal haemorrhage—Thalidomide—leprosy	0.0017	0.00443	CcSEcCtD
Rasagiline—Osteoarthritis—Thalidomide—leprosy	0.0017	0.00443	CcSEcCtD
Rasagiline—Diplopia—Thalidomide—leprosy	0.0017	0.00443	CcSEcCtD
Rasagiline—Disturbance in sexual arousal—Thalidomide—leprosy	0.00169	0.0044	CcSEcCtD
Rasagiline—BCL2—IL-2 Signaling Pathway—IL2—leprosy	0.00167	0.0193	CbGpPWpGaD
Rasagiline—Migraine—Thalidomide—leprosy	0.00167	0.00436	CcSEcCtD
Rasagiline—Affect lability—Thalidomide—leprosy	0.00167	0.00436	CcSEcCtD
Rasagiline—Psychotic disorder—Thalidomide—leprosy	0.00166	0.00433	CcSEcCtD
Rasagiline—Face oedema—Thalidomide—leprosy	0.00164	0.00428	CcSEcCtD
Rasagiline—Mood swings—Thalidomide—leprosy	0.00161	0.0042	CcSEcCtD
Rasagiline—Ataxia—Thalidomide—leprosy	0.0016	0.00417	CcSEcCtD
Rasagiline—Liver function test abnormal—Thalidomide—leprosy	0.00157	0.00409	CcSEcCtD
Rasagiline—Orthostatic hypotension—Thalidomide—leprosy	0.00155	0.00405	CcSEcCtD
Rasagiline—BCL2—IL2-mediated signaling events—IFNG—leprosy	0.00154	0.0178	CbGpPWpGaD
Rasagiline—Muscular weakness—Thalidomide—leprosy	0.0015	0.00391	CcSEcCtD
Rasagiline—BCL2—HIV-1 Nef: Negative effector of Fas and TNF-alpha—TNF—leprosy	0.00148	0.0171	CbGpPWpGaD
Rasagiline—Insomnia—Dapsone—leprosy	0.00147	0.00385	CcSEcCtD
Rasagiline—Dysphagia—Thalidomide—leprosy	0.00147	0.00383	CcSEcCtD
Rasagiline—Influenza—Thalidomide—leprosy	0.00147	0.00383	CcSEcCtD
Rasagiline—BCL2—ATF-2 transcription factor network—IFNG—leprosy	0.00143	0.0166	CbGpPWpGaD
Rasagiline—Angina pectoris—Thalidomide—leprosy	0.00143	0.00373	CcSEcCtD
Rasagiline—BCL2—IL2-mediated signaling events—IL2—leprosy	0.00137	0.0158	CbGpPWpGaD
Rasagiline—Upper respiratory tract infection—Thalidomide—leprosy	0.00136	0.00356	CcSEcCtD
Rasagiline—Pollakiuria—Thalidomide—leprosy	0.00136	0.00354	CcSEcCtD
Rasagiline—Erectile dysfunction—Thalidomide—leprosy	0.00135	0.00353	CcSEcCtD
Rasagiline—Photosensitivity reaction—Thalidomide—leprosy	0.00134	0.0035	CcSEcCtD
Rasagiline—Gastrointestinal pain—Dapsone—leprosy	0.00133	0.00348	CcSEcCtD
Rasagiline—Weight decreased—Thalidomide—leprosy	0.00133	0.00347	CcSEcCtD
Rasagiline—BCL2—Amyotrophic lateral sclerosis (ALS)—TNF—leprosy	0.00132	0.0152	CbGpPWpGaD
Rasagiline—Infestation NOS—Thalidomide—leprosy	0.00131	0.00342	CcSEcCtD
Rasagiline—Infestation—Thalidomide—leprosy	0.00131	0.00342	CcSEcCtD
Rasagiline—Depression—Thalidomide—leprosy	0.00131	0.00341	CcSEcCtD
Rasagiline—Acute coronary syndrome—Thalidomide—leprosy	0.00129	0.00337	CcSEcCtD
Rasagiline—Abdominal pain—Dapsone—leprosy	0.00129	0.00336	CcSEcCtD
Rasagiline—Body temperature increased—Dapsone—leprosy	0.00129	0.00336	CcSEcCtD
Rasagiline—Myocardial infarction—Thalidomide—leprosy	0.00128	0.00335	CcSEcCtD
Rasagiline—Neuropathy peripheral—Thalidomide—leprosy	0.00128	0.00335	CcSEcCtD
Rasagiline—Stomatitis—Thalidomide—leprosy	0.00128	0.00333	CcSEcCtD
Rasagiline—Conjunctivitis—Thalidomide—leprosy	0.00127	0.00332	CcSEcCtD
Rasagiline—Sweating—Thalidomide—leprosy	0.00125	0.00327	CcSEcCtD
Rasagiline—Haematuria—Thalidomide—leprosy	0.00125	0.00326	CcSEcCtD
Rasagiline—Epistaxis—Thalidomide—leprosy	0.00123	0.00322	CcSEcCtD
Rasagiline—BCL2—FAS pathway and Stress induction of HSP regulation—TNF—leprosy	0.00122	0.0141	CbGpPWpGaD
Rasagiline—Rhinitis—Thalidomide—leprosy	0.00118	0.00307	CcSEcCtD
Rasagiline—Hypoaesthesia—Thalidomide—leprosy	0.00117	0.00305	CcSEcCtD
Rasagiline—Urinary tract disorder—Thalidomide—leprosy	0.00116	0.00303	CcSEcCtD
Rasagiline—Oedema peripheral—Thalidomide—leprosy	0.00116	0.00302	CcSEcCtD
Rasagiline—Urethral disorder—Thalidomide—leprosy	0.00115	0.00301	CcSEcCtD
Rasagiline—Eye disorder—Thalidomide—leprosy	0.0011	0.00287	CcSEcCtD
Rasagiline—BCL2—Ceramide signaling pathway—TNF—leprosy	0.00109	0.0126	CbGpPWpGaD
Rasagiline—Cardiac disorder—Thalidomide—leprosy	0.00109	0.00285	CcSEcCtD
Rasagiline—Angiopathy—Thalidomide—leprosy	0.00107	0.00278	CcSEcCtD
Rasagiline—Immune system disorder—Thalidomide—leprosy	0.00106	0.00277	CcSEcCtD
Rasagiline—Mediastinal disorder—Thalidomide—leprosy	0.00106	0.00276	CcSEcCtD
Rasagiline—Chills—Thalidomide—leprosy	0.00105	0.00275	CcSEcCtD
Rasagiline—BCL2—C-MYB transcription factor network—CD4—leprosy	0.00104	0.0121	CbGpPWpGaD
Rasagiline—Alopecia—Thalidomide—leprosy	0.00104	0.00271	CcSEcCtD
Rasagiline—Vomiting—Dapsone—leprosy	0.00104	0.00271	CcSEcCtD
Rasagiline—Mental disorder—Thalidomide—leprosy	0.00103	0.00269	CcSEcCtD
Rasagiline—Malnutrition—Thalidomide—leprosy	0.00102	0.00267	CcSEcCtD
Rasagiline—Headache—Dapsone—leprosy	0.00102	0.00267	CcSEcCtD
Rasagiline—Flatulence—Thalidomide—leprosy	0.00101	0.00263	CcSEcCtD
Rasagiline—Dysgeusia—Thalidomide—leprosy	0.001	0.00261	CcSEcCtD
Rasagiline—Back pain—Thalidomide—leprosy	0.000989	0.00258	CcSEcCtD
Rasagiline—Muscle spasms—Thalidomide—leprosy	0.000983	0.00257	CcSEcCtD
Rasagiline—Nausea—Dapsone—leprosy	0.000969	0.00253	CcSEcCtD
Rasagiline—Tremor—Thalidomide—leprosy	0.000958	0.0025	CcSEcCtD
Rasagiline—BCL2—Caspase Cascade in Apoptosis—TNF—leprosy	0.000954	0.011	CbGpPWpGaD
Rasagiline—Ill-defined disorder—Thalidomide—leprosy	0.000949	0.00248	CcSEcCtD
Rasagiline—Anaemia—Thalidomide—leprosy	0.000945	0.00247	CcSEcCtD
Rasagiline—Agitation—Thalidomide—leprosy	0.00094	0.00245	CcSEcCtD
Rasagiline—Malaise—Thalidomide—leprosy	0.000922	0.00241	CcSEcCtD
Rasagiline—Vertigo—Thalidomide—leprosy	0.000919	0.0024	CcSEcCtD
Rasagiline—Syncope—Thalidomide—leprosy	0.000917	0.00239	CcSEcCtD
Rasagiline—Leukopenia—Thalidomide—leprosy	0.000916	0.00239	CcSEcCtD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—IFNG—leprosy	0.000904	0.0104	CbGpPWpGaD
Rasagiline—Loss of consciousness—Thalidomide—leprosy	0.000899	0.00235	CcSEcCtD
Rasagiline—BCL2—Corticotropin-releasing hormone—IL2—leprosy	0.000893	0.0103	CbGpPWpGaD
Rasagiline—Cough—Thalidomide—leprosy	0.000893	0.00233	CcSEcCtD
Rasagiline—Convulsion—Thalidomide—leprosy	0.000886	0.00231	CcSEcCtD
Rasagiline—Hypertension—Thalidomide—leprosy	0.000883	0.0023	CcSEcCtD
Rasagiline—Chest pain—Thalidomide—leprosy	0.000871	0.00227	CcSEcCtD
Rasagiline—Arthralgia—Thalidomide—leprosy	0.000871	0.00227	CcSEcCtD
Rasagiline—Anxiety—Thalidomide—leprosy	0.000868	0.00226	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.000865	0.00226	CcSEcCtD
Rasagiline—Discomfort—Thalidomide—leprosy	0.00086	0.00224	CcSEcCtD
Rasagiline—Dry mouth—Thalidomide—leprosy	0.000852	0.00222	CcSEcCtD
Rasagiline—Confusional state—Thalidomide—leprosy	0.000842	0.0022	CcSEcCtD
Rasagiline—Infection—Thalidomide—leprosy	0.000829	0.00216	CcSEcCtD
Rasagiline—Shock—Thalidomide—leprosy	0.000821	0.00214	CcSEcCtD
Rasagiline—Nervous system disorder—Thalidomide—leprosy	0.000819	0.00214	CcSEcCtD
Rasagiline—Skin disorder—Thalidomide—leprosy	0.000811	0.00212	CcSEcCtD
Rasagiline—Hyperhidrosis—Thalidomide—leprosy	0.000807	0.00211	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—CYLD—leprosy	0.000796	0.0092	CbGpPWpGaD
Rasagiline—Anorexia—Thalidomide—leprosy	0.000796	0.00208	CcSEcCtD
Rasagiline—Hypotension—Thalidomide—leprosy	0.00078	0.00204	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Thalidomide—leprosy	0.000761	0.00198	CcSEcCtD
Rasagiline—Insomnia—Thalidomide—leprosy	0.000755	0.00197	CcSEcCtD
Rasagiline—Paraesthesia—Thalidomide—leprosy	0.00075	0.00196	CcSEcCtD
Rasagiline—Dyspnoea—Thalidomide—leprosy	0.000744	0.00194	CcSEcCtD
Rasagiline—Somnolence—Thalidomide—leprosy	0.000742	0.00194	CcSEcCtD
Rasagiline—Dyspepsia—Thalidomide—leprosy	0.000735	0.00192	CcSEcCtD
Rasagiline—Decreased appetite—Thalidomide—leprosy	0.000726	0.00189	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Thalidomide—leprosy	0.000721	0.00188	CcSEcCtD
Rasagiline—Constipation—Thalidomide—leprosy	0.000714	0.00186	CcSEcCtD
Rasagiline—BCL2—Apoptosis—TNF—leprosy	0.000699	0.00808	CbGpPWpGaD
Rasagiline—Feeling abnormal—Thalidomide—leprosy	0.000688	0.00179	CcSEcCtD
Rasagiline—Gastrointestinal pain—Thalidomide—leprosy	0.000683	0.00178	CcSEcCtD
Rasagiline—Urticaria—Thalidomide—leprosy	0.000663	0.00173	CcSEcCtD
Rasagiline—Abdominal pain—Thalidomide—leprosy	0.00066	0.00172	CcSEcCtD
Rasagiline—Body temperature increased—Thalidomide—leprosy	0.00066	0.00172	CcSEcCtD
Rasagiline—Hypersensitivity—Thalidomide—leprosy	0.000615	0.0016	CcSEcCtD
Rasagiline—Asthenia—Thalidomide—leprosy	0.000599	0.00156	CcSEcCtD
Rasagiline—Pruritus—Thalidomide—leprosy	0.000591	0.00154	CcSEcCtD
Rasagiline—Diarrhoea—Thalidomide—leprosy	0.000571	0.00149	CcSEcCtD
Rasagiline—Dizziness—Thalidomide—leprosy	0.000552	0.00144	CcSEcCtD
Rasagiline—Vomiting—Thalidomide—leprosy	0.000531	0.00138	CcSEcCtD
Rasagiline—Rash—Thalidomide—leprosy	0.000526	0.00137	CcSEcCtD
Rasagiline—Dermatitis—Thalidomide—leprosy	0.000526	0.00137	CcSEcCtD
Rasagiline—Headache—Thalidomide—leprosy	0.000523	0.00136	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—TLR2—leprosy	0.000513	0.00593	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—RIPK2—leprosy	0.000513	0.00593	CbGpPWpGaD
Rasagiline—Nausea—Thalidomide—leprosy	0.000496	0.00129	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—NOD2—leprosy	0.000465	0.00537	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CYLD—leprosy	0.000464	0.00536	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—SDHD—leprosy	0.000434	0.00501	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TNF—leprosy	0.000428	0.00495	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—leprosy	0.000417	0.00481	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PARK2—leprosy	0.00041	0.00473	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—leprosy	0.00037	0.00428	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TNF—leprosy	0.000363	0.00419	CbGpPWpGaD
Rasagiline—BCL2—Immune System—RIPK2—leprosy	0.000299	0.00345	CbGpPWpGaD
Rasagiline—BCL2—Immune System—TLR2—leprosy	0.000299	0.00345	CbGpPWpGaD
Rasagiline—BCL2—Immune System—NOD2—leprosy	0.000271	0.00313	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—TNF—leprosy	0.00027	0.00311	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—leprosy	0.00027	0.00311	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD40LG—leprosy	0.000229	0.00265	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD8A—leprosy	0.000227	0.00262	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CD4—leprosy	0.000223	0.00258	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HLA-DRB1—leprosy	0.000184	0.00213	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IFNG—leprosy	0.000135	0.00156	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD4—leprosy	0.00013	0.0015	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL2—leprosy	0.00012	0.00138	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SDHD—leprosy	0.0001	0.00116	CbGpPWpGaD
